8-K: TOI Reaffirms 2025 Guidance, Projects 2026 Profitability

The Oncology Institute, Inc. reaffirmed its 2025 financial guidance and provided a preliminary 2026 outlook, projecting its first full year of Adjusted EBITDA profitability as a public company.

Summary

• Reaffirmed 2025 financial guidance.
• Provided preliminary 2026 financial outlook and longer-term guidance through 2028.
• Anticipates 2026 total revenue between $630 million and $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges.
• 2026 revenue includes approximately $150 million of Capitation revenue.
• Projected 2026 Adjusted EBITDA is in the range of $0 million to $9 million.
• The midpoint of the 2026 Adjusted EBITDA range would mark the company's first full year of Adjusted EBITDA profitability as a public company.
• Longer-term, through 2028, expects total revenue to grow at an annual rate of approximately 20%.
• Capitation and Dispensary revenue are projected to increase to approximately 30% and 50% of total revenue, respectively, by 2028.
• Margins are expected to expand to the mid-single-digit range as a percentage of revenue by 2028.

Sentiment

Score: 7

Explanation: The filing presents a positive outlook with strong revenue growth projections and anticipated Adjusted EBITDA profitability for 2026, along with longer-term margin expansion. However, the initial profitability range for 2026 is modest, and full realization of new contract economics is delayed to 2027, tempering the immediate positive impact.

Positives

• Projected 28% revenue growth for 2026, with total revenue anticipated to be between $630 million and $650 million.
• Anticipates the first full year of Adjusted EBITDA profitability as a public company in 2026, with a range of $0 million to $9 million.
• Strong longer-term outlook through 2028, targeting approximately 20% annual revenue growth.
• Expected margin expansion to the mid-single-digit range as a percentage of revenue by 2028, driven by the expansion of the asset-light delegated capitated model and continued SG&A leverage.
• Continued expansion of delegated contracts in Florida and the annualized impact of strong volumes in the Dispensary segment during the second half of 2025 are expected to drive revenue growth.
• The business model is migrating towards comprehensive oncology care in an increasingly value-based landscape, aligning with industry trends.

Negatives

• Profitability from newly onboarded delegated contracts is expected to build progressively over the course of 2026, with more fully realized economics anticipated in 2027, indicating a delayed impact on immediate profitability.
• The Adjusted EBITDA range for 2026 starts at $0 million, suggesting the potential for minimal or no profitability despite significant revenue growth.
• A quantitative reconciliation for forward-looking Adjusted EBITDA to net (loss) income, the most directly comparable GAAP financial measure, is not provided due to the 'unreasonable efforts exception' under Regulation S-K, citing uncertainties regarding various financial items.

Risks

• The accuracy of the assumptions underlying the 2026 full fiscal year outlook and the longer-term outlook with respect to Adjusted EBITDA and margins.
• The outcome of judicial and administrative proceedings to which the company may become a party or investigations to which it may become or is subject, which could interrupt or limit operations, result in adverse judgments, settlements or fines, and create negative publicity.
• Changes in patient or payors' preferences, prospects, and the competitive conditions prevailing in the healthcare sector.
• Failure to continue to meet stock exchange listing standards.
• The impact of a cybersecurity incident affecting a software provider on the company's business.
• Additional risks that the company is currently evaluating or does not presently know or that it currently believes are immaterial, which could also cause actual results to differ from those contained in the forward-looking statements.

Future Outlook

The company anticipates total revenue for 2026 to be between $630 million and $650 million, driven by contract expansion, strong dispensary volumes, and organic growth, with Adjusted EBITDA projected to be $0 million to $9 million, potentially marking its first full year of profitability. Beyond 2026, the company expects approximately 20% annual revenue growth through 2028, with Capitation and Dispensary revenue increasing to 30% and 50% of total revenue, respectively, and margins expanding to the mid-single-digit range.

Management Comments

• We believe the Company is well positioned for continued expansion.
• We seek to grow total revenue at an annual rate of approximately 20% through 2028.
• We believe margins have the potential to expand through 2028 to the mid-single-digit range as a percentage of revenue.

Industry Context

The Oncology Institute operates in the rapidly evolving healthcare sector, specifically in oncology, with a stated focus on value-based care. This strategy aligns with broader industry trends towards cost-effective, outcome-driven patient care models, moving away from traditional fee-for-service. The emphasis on expanding delegated contracts and increasing capitation revenue reflects a shift towards risk-sharing models common in managed care, positioning TOI to capitalize on the growing demand for integrated cancer treatment in community settings.

Legal Proceedings

• Potential judicial and administrative proceedings or investigations that could interrupt or limit operations, result in adverse judgments, settlements or fines, and create negative publicity.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through projected revenue growth, anticipated profitability, and margin expansion. However, the initial modest EBITDA and delayed full profitability from new contracts could impact short-term sentiment.
• Patients: Continued expansion of specialized, value-based cancer care, including clinical trials and advanced care models, across more locations.
• Employees/Clinicians: Continued growth and expansion may lead to increased opportunities, but targeted investments for growth could also imply operational adjustments.
• Payors: Expansion of delegated contracts and migration to value-based models indicate deeper partnerships and risk-sharing arrangements.

Next Steps

• Continued expansion of delegated contracts in Florida.
• Ongoing organic growth and new contract wins across the platform.
• Targeted investments to support ongoing growth.
• Progressive build-up of profitability from newly onboarded delegated contracts over 2026, with full realization in 2027.
• Continued scaling of the company to expand margins through 2028.

Key Dates

Recommendation

The Oncology Institute's reaffirmation of 2025 guidance and preliminary 2026 outlook, projecting its first full year of Adjusted EBITDA profitability as a public company, is a positive development. The strong revenue growth forecast and longer-term margin expansion potential are encouraging. However, the initial 2026 Adjusted EBITDA range is modest ($0M-$9M), and the full economic benefits of new delegated contracts are not expected until 2027, indicating a slower ramp-up to significant profitability. The 'unreasonable efforts' exception for GAAP reconciliation also adds a layer of uncertainty. Given the positive long-term trajectory but tempered short-term profitability and inherent risks in healthcare, a 'hold' recommendation is appropriate for investors to observe the execution of these growth and profitability initiatives.

Keywords

Oncology, Healthcare, Value-Based Care, Financial Guidance, EBITDA, Revenue Growth, Capitation, Dispensary, SEC Filing, TOI, Cancer Care